
    
      PRIMARY OBJECTIVES:

      I. To determine if changes in islet cell physiology are detectable before or after matched
      related donor (MRD) hematopoietic stem cell transplant (HCT) in patients developing new-onset
      post-transplant diabetes mellitus (PTDM).

        1. To determine if a compensatory increase in glucose stimulated insulin secretion (GSIS)
           by β-cells precedes PTDM development in patients without diabetes undergoing MRD HCT.

        2. To determine if excess glucagon secretion and impaired α-cell response to glucose or
           GLP-1 contributes to the hyperglycemia of PTDM.

      II. To determine if the IL-33/ST2 axis promotes immune/islet cell dysregulation during PTDM.

      OUTLINE:

      Patients undergo 2 OGTTs and a standard hyperglycemic clamp procedure prior to HCT. Patients
      then undergo repeat OGTTs and a hyperglycemic clamp procedure once after HCT between days
      80-100.
    
  